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ABSTRACT: Mammalian target of rapamycin (mTOR) signaling is a core pathway in cellular metabolism, and control of the
mTOR pathway by rapamycin shows potential for the treatment of metabolic diseases. In this study, we employed a new
proximity biotin-labeling method using promiscuous biotin ligase (pBirA) to identify unknown elements in the rapamycin-
induced interactome on the FK506-rapamycin binding (FRB) domain in living cells. FKBP25 showed the strongest biotin
labeling by FRB−pBirA in the presence of rapamycin. Immunoprecipitation and immunoﬂuorescence experiments conﬁrmed
that endogenous FKBP25 has a rapamycin-induced physical interaction with the FRB domain. Furthermore, the crystal structure
of the ternary complex of FRB−rapamycin−FKBP25 was determined at 1.67-Å resolution. In this crystal structure we found that
the conformational changes of FRB generate a hole where there is a methionine-rich space, and covalent metalloid coordination
was observed at C2085 of FRB located at the bottom of the hole. Our results imply that FKBP25 might have a unique
physiological role related to metallomics in mTOR signaling.
■ INTRODUCTION
Recently, proximity-directed labeling methods1−3 have been
developed based on enzymatic reactions that are mediated by
engineered ascorbate peroxidase4−6 or promiscuous biotin
ligase (pBirA).7−12 In the pBirA method, an in situ reactive
biotin-activated ester can be generated in living cells, such as
biotin-adenosine-5′-monophosphoester (biotin-AMP), that
preferentially reacts with the lysine residues of neighboring
proteins. Because this labeling occurs via covalent bond
formation, the labeled proteins can be isolated by standard
pull-down methods using streptavidin (SA) beads and are then
readily identiﬁed by mass spectrometry. Using these methods,
collectively referred to as BioID, many interesting subcompart-
mental-localized proteomes such as the nuclear envelope
membrane proteome,7 nuclear pore complex,8,13 centrosome,10
centrosome−cilium interface,11 and cadherin complex12 have
been recently identiﬁed.
In these methods, the mass identiﬁcation of biotin-labeled
proteins is usually performed by detection of unlabeled
peptides from labeled proteins after proteolysis and enrich-
ment, because the population of unlabeled peptides is more
abundant than the labeled peptide population. To discriminate
between unlabeled peptides following a labeling event (Protein
X and Y in Scheme 1) and nonspeciﬁc bead-binding proteins
(Protein Z in Scheme 1), unlabeled peptides can be tagged with
a diﬀerent isotope composition [e.g., SILAC4,5 or iTRAQ6]
during the sample preparation, and then peptides from a
labeling event can be identiﬁed according to the expected
isotopic ratio. However, this identiﬁcation method based on
unlabeled peptides has a caveat. As shown in Scheme 1, if an
unlabeled protein (Protein Y) has strong binding aﬃnity
toward a labeled protein (Protein X) and can survive on the
bead during the washing step, the identiﬁed peptides from this
unlabeled protein (Protein Y) could be mistakenly regarded as
a “labeled protein.” Therefore, the most direct method to
identify a proximity-labeled protein is to identify a biotin-
labeled peptide after enrichment; however, no such method has
been reported to date. Thus, we tested whether our new
proximity-labeled protein ID method (Spot-BioID) could
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identify the rapamycin-induced interacting protein of the
FK506-rapamycin binding (FRB) domain of mammalian target
of rapamycin (mTOR).
Rapamycin is a macrocyclic small molecule that is
synthesized by soil bacteria, including Streptomyces hygroscopi-
cus. Rapamycin was ﬁrst identiﬁed as an antifungal agent but
has also been shown to possess immunosuppressive14 and
anticancer activity.15 Recently, rapamycin treatment was also
shown to prevent pathological protein aggregation in neuro-
logical disorders by recruiting autophagy activity and could
inhibit epileptic seizures in mice.16 Rapamycin treatment was
also shown to be eﬀective in prolonging the lifespans of various
experimental models, including mice.17
In mammals, several FK506-binding proteins (FKBPs) have
been identiﬁed as rapamycin-binding proteins,18 including
FKBP12, which forms a heterodimer complex with mTOR
and allosterically inhibits its activity.19 Because mTOR signaling
is a core pathway to regulate cell growth and cellular
metabolism, controlling the mTOR pathway by rapamycin
has been proposed as a potentially useful treatment in diverse
human diseases such as cancer, diabetes, obesity, neurological
diseases, and genetic disorders.20
mTOR is a large protein (288 kDa), and its small domain,
the FRB domain (11 kDa, amino acids 2021−2113), is
responsible for FKBP12−rapamycin binding.19 The crystal
structure of the ternary complex of FRB−rapamycin−FKBP12
revealed that FRB and FKBP12 occupy two diﬀerent
hydrophobic faces of rapamycin simultaneously.21 Because
protein−protein interactions between FRB and FKBP12 only
occur in the presence of rapamycin, many biotechnologies have
been developed to achieve spatiotemporal control of protein
translocation22−25 and enzyme activity.26−32 In addition, this
complex also provides a model system for studying
Scheme 1. MS Analysis of Biotin-Labeled Proteins Produced by Proximity Labeling
ACS Central Science Research Article
DOI: 10.1021/acscentsci.6b00137
ACS Cent. Sci. 2016, 2, 506−516
507
spatiotemporal protein−protein interactions for the develop-
ment of various types of genetically encoded tags.33−35
FKBP12 is currently recognized as the exclusive main protein
factor controlling mTOR activity in the presence of rapamycin.
However, there are also several other reported FKBP proteins
with the potential to have rapamycin-induced interactions with
mTOR.36,37 Thus, in this study, we tested the ability of our new
proximity labeling ID method to determine whether FKBP12 is
the only major interactor of FRB, and whether the method
could reveal other binding partners that have not been
previously characterized by conventional methods.
■ RESULTS
MS/MS Identiﬁcation of Proximity-Labeled Proteins.
We conducted proximity labeling experiment with FRB−pBirA
in living cells. FRB−pBirA showed a whole-cell expression
pattern, and the biotinylation activity of FRB−pBirA seemed
promising in both the rapamycin-treated and control cells
(Figure 1B). We further assessed whether FRB−pBirA labeled
a distinct protein population in a living cell by conducting a
Western blot experiment (Figure 1C, see Experimental
Section). FRB−pBirA generated numerous biotinylated protein
bands, and these band patterns were very similar between the
rapamycin-treated sample (FRB-R) and the no rapamycin-
treated sample (FRB-NoR) (lanes 1 and 2, Figure 1C).
However, we observed one very strongly biotin-labeled protein
at around 25 kDa in the SA-HRP pattern of the FRB-R sample
(lane 1, Figure 1C), which did not appear in the FRB-NoR
sample (lane 2, Figure 1C). We also found that this 25-kDa
protein was reproducibly labeled by rapamycin treatment in all
stable cell clones of FRB−pBirA constructed in HEK293T-Rex
cells (Figure 1D). We postulated that this protein was most
likely labeled by interacting with FRB−pBirA in the presence of
rapamycin. However, the labeled protein could not be FKBP12
because FKBP12 (12 kDa) could not be detected at 25 kDa in a
denaturing SDS−PAGE gel. Thus, we attempted to identify this
protein among the labeled peptides using the Spot-BioID
workﬂow (Scheme 1).
To identify biotin-labeled proteins by FRB−pBirA, we
performed two independent pBirA-labeling experiments for
stably expressed FRB-R and FRB−pBirA in HEK293T-Rex
cells. For direct observation of each biotinylated peptide per
sample, we expected to observe biotin-attached modiﬁcation of
the lysine residue (Lys + 226 Da), because the primary amine
of lysine is a major target of the biotin-AMP ester.7 Thus, we
designed our workﬂow to focus on the enrichment of
biotinylated peptides via on-bead trypsin digestion after
streptavidin-bead enrichment (see Experimental Section).
This procedure allowed us to reduce the sample complexity
because most of the abundant unlabeled peptides could be
washed out at this step.
From the MS/MS-identiﬁed biotin-labeled peptides (see
Experimental Section), we extracted the “labeled site”
information on each labeled peptide, because there were
many cases in which the same modiﬁed sites were redundantly
identiﬁed in diﬀerent partially trypsin-digested peptides. Then,
the extracted labeled sites that were reproducibly found within
both replicates were ﬁnally selected. From this stringent
analysis, we extracted a total of 92 unique labeled sites, which
could be clustered into three groups (Group I to III) according
to the level of overlap between the FRB-R and FRB-NoR
samples (Figure 2A).
Identiﬁcation of the Rapamycin-Induced Interactome
by Subtraction of Background Labeled Sites. We found a
considerable number of labeled sites that overlapped between
the FRB-R and FRB-NoR samples. These overlapping labeled
biotinylation sites (Group I) should be regarded as the FRB-
interactome. In Group I, a total of 63 biotin-labeled sites were
found among 57 identiﬁed proteins. This considerable overlap
should be related to the similar biotinylated band pattern
observed for FRB−pBirA (Figure 1D) regardless of rapamycin
treatment.
Interestingly, we also found several proteins, including ECD,
FEN1, FKBP25, GSPT1, LARP1, PCNP, and TIPRL, that were
exclusively labeled by FRB−pBirA only when the cells were
treated with rapamycin (Group II) (Figure 2B). This suggests
that the proteins in Group II are highly likely to be rapamycin-
induced interaction partners of FRB in living cells. In this
group, we found reasonable evidence of associations of LARP1,
TIPRL, and FKBP25 with mTOR or rapamycin according to
the literature. LARP1 is known to regulate mTOR activity by
Figure 1. Proximity labeling of FRB−pBirA in living cells. (A)
Schematic representation of the proximity labeling reactions of FRB-
conjugated promiscuous biotin ligase (FRB−pBirA) in the presence of
rapamycin. Circle R represents rapamycin and circle B represents
biotin. The chemical structure of rapamycin is shown. (B) Confocal
images of the expression of FRB−pBirA and its biotinylation protein
pattern with rapamycin or without rapamycin treatment for 16 h in
U2OS cells. Scale bar = 10 μm. (C) Streptavidin (SA)-HRP Western
blot of proteins biotinylated by transiently expressed FRB−pBirA with
or without rapamycin treatment for 16 h in HEK293T cells. (D) SA-
HRP Western blot of biotinylated proteins and anti-HA Western blot
of stably expressed FRB−pBirA in diﬀerent stable clones of
HEK293T-Rex cells. Strongly biotinylated protein around 25 kDa is
marked with an asterisk, and self-labeled FRB−pBirA (molecular mass
= 48.5 kDa) is marked with a black arrow in (C) and (D).
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post-transcription control, TIPRL is known to act on mTORC1
signaling in conditions of amino acid starvation,38 and FKBP25
is a rapamycin-binding protein.39 It is noteworthy that only
FKBP25 (also known as FKBP3) showed multiple biotin-
labeled sites (K80, K86, K89) among the Group II proteins
(Figure 3), which indicates that strong proximity-driven
labeling occurred on FKBP25 by FRB−pBirA in the presence
of rapamycin.
We also found that some proteins were exclusively labeled by
FRB−pBirA in the absence of rapamycin (Group III). In this
group, we found that ARID3B, BCLAF1, CXorf56, DDX42,
IBTKIK, ISY1, LIMA1, PGRMC1, PGRMC2, POLDIP3,
Figure 2. Proteomic analysis of proteins proximity-labeled by FRB−pBirA with or without rapamycin treatment. (A) Overview of 92 sites biotin-
labeled by stably expressed FRB−pBirA in HEK293T-Rex cells with or without rapamycin treatment. Color intensity represents the unique spectral
counts of each labeled site per biological replicate. Detailed information regarding the identiﬁed labeled site for each labeled protein is shown in
Supplementary Data Set 1, Supporting Information. (B) Rapamycin-dependent biotin labeling of proteins by FRB−pBirA. Upper protein cluster
shows proteins that contain sites exclusively biotin-labeled by FRB−pBirA in the absence of rapamycin (Group III), and lower protein cluster shows
proteins that contain sites exclusively biotin-labeled by FRB−pBirA in the presence of rapamycin (Group II). Proteins with previously reported
functions are marked by a diﬀerent color.
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RPA1, RPAP3, SART1, SF3A1, SF3B2, SKP1, TFIP11, and
USP15 were exclusively labeled by FRB−pBirA only in the
absence of rapamycin. We hypothesize that these proteins
should have a temporal interaction with FRB and could be
dissociated by other rapamycin-induced interacting proteins in
the presence of rapamycin.
From bioinformatics analysis, we found that the proteins in
Group II and Group III have well-separated genetic networks;
Group II genes have a functional linkage to the poly
adenylation complex of mRNA, whereas Group III genes are
connected to the mRNA splicing complex (see Supporting
Information). From this analysis, we speculate that the
rapamycin-controlled pathway might be related to diﬀerent
stages of mRNA processing.
FKBP25 Is the 25-kDa Protein Biotinylated by FRB−
pBirA in the Presence of Rapamycin. Among the Group II
proteins, FKBP25 is a 25-kDa protein that has a rapamycin-
binding domain similar to other FKBP proteins. It shares an
FKBP-type peptidyl-prolyl isomerase (PPIase) domain at the
C-terminus domain with other FKBP proteins such as
FKBP1218 (Figure 4A). However, there has been no study
investigating whether FKBP25 has a rapamycin-induced
physical interaction with FRB in living mammalian cells
reported to date. Thus, we designed several follow-up
experiments to explore and conﬁrm whether FKBP25 has a
true rapamycin-induced interaction with FRB.
First, we performed an immunoprecipitation experiment to
conﬁrm that FKBP25 was enriched in the biotinylated protein
pools of the FRB-R sample. For this study, we respectively
enriched the biotinylated proteins of the FRB-R and FRB-NoR
samples using streptavidin magnetic beads, and the enriched
proteins were transferred to a nitrocellulose membrane and
immunoblotted with anti-FKBP25. As shown in Figure 4B,
FKBP25 was enriched in the SA-enriched sample of rapamycin-
treated FRB−pBirA but not in the no-rapamycin treatment.
Figure 3. Representative MS/MS spectrum of labeled peptide of FKBP25. (A) MS/MS spectra of biotin-labeled peptides of K80-, K86-, and K89-
labeled sites of FKBP25. (B) MS/MS spectrum of double biotin-labeled peptides (K86 and K89) of FKBP25. This spectrum was observed in the MS
analysis of the FRB−pBirA transfected sample in the presence of rapamycin.
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We performed another immunoprecipitation experiment by
using anti-FKBP25 to pull-down endogenous FKBP25 proteins
from the whole cell lysate and checked whether endogenous
FKBP25 was biotinylated using an SA-HRP Western blot. As
shown in Figure 4C, endogenous FKBP25 in FRB−pBirA was
biotinylated in the FRB-R sample, and endogenous FKBP25 in
the FRB-NoR showed no biotinylation. In this experiment, we
also found that a strongly biotinylated 25-kDa protein band in
the whole cell lysate of the FRB-R sample was depleted in the
ﬂow-through sample with anti-FKBP25 immunoprecipitation,
and enriched FKBP25 showed a strong biotinylated signal with
the same molecular weight. This result provides further support
that FKBP25 is the 25-kDa protein that was observed to be the
most strongly biotinylated by FRB−pBirA in the presence of
rapamycin (Figure 1C,D).
FKBP25 Physically Interacts with FRB in the Presence
of Rapamycin in Living Cells. Next, we attempted to check
whether FKBP25 physically interacts with FRB in the presence
of rapamycin in a living cell. Previously, it has been
demonstrated that FKBP12 and FRB physically interact in
rapamycin-treated cells by imaging FKBP12-tagged protein
translocation to artiﬁcially FRB-targeted spaces.22−25 Thus, we
employed this translocation assay to check for a protein−
protein interaction between FKBP25 and FRB in living cells.
For this assay, we employed FRB-OMM, which is a fusion
construct of FRB to the OMM domain of monoamine oxidase
that targets the outer membrane of the mitochondria.22 After
transient expression of FRB-OMM, we checked the localization
patterns of endogenous FKBP25 by incubation with an anti-
FKBP25 antibody in rapamycin-treated and nontreated
samples. As shown in Figure 4D, FKBP25 in the rapamycin-
treated sample clearly localized in the mitochondria, but the
same protein showed cytosolic localization without rapamycin
treatment. This result indicates that FKBP25 and FRB
physically interact only in the presence of rapamycin, as
expected (Figure 4D). We further conﬁrmed that the
exogenously expressed FKBP25-tagged protein (FKBP25-V5-
APEX2) is also translocated to FRB-OMM in the presence of
rapamycin (Figure S1). This result indicates that FKBP25−
FRB can be utilized as a genetically encoded chemical-induced
protein dimerization tool, similar to FKBP12−FRB.40
It is noteworthy that the immunoﬂuorescence images of
FKBP25 showed a clear cytoplasmic pattern and did not
localize to the nucleus. Several earlier studies of FKBP25
Figure 4. FKBP25 is a newly identiﬁed rapamycin-induced FRB-interacting protein. (A) MS-identiﬁed sites (K80, K86, K89) of FKBP25 biotin-
labeled by FRB−pBirA. In the crystal structure of FKBP25 (PDB ID: 2MPH), the labeled lysine residues are green-colored. (B)
Immunoprecipitation of biotinylated FKBP25 in the FRB-R sample by streptavidin. Streptavidin beads were used for pull-down, and anti-
FKBP25 antibody was used for immunoblot. (C) Immunoprecipitation of biotinylated FKBP25 in FRB-R samples by anti-FKBP25. Anti-FKBP25
was used for pull-down, and streptavidin-HRP (SA-HRP) was used for immunoblot. Biotinylated FKBP25 is marked with an asterisk. Self-labeled
FRB−pBirA is marked with a black arrow. The eluted heavy chain and light chain of the antibody are marked by blank arrows. (D) Confocal imaging
of in vivo protein translocation of endogenous FKBP25 using transfected FRB-OMM (outer mitochondrial membrane) in HeLa cells. Scale bar = 10
μm (left). Schematic representation is shown on the right.
ACS Central Science Research Article
DOI: 10.1021/acscentsci.6b00137
ACS Cent. Sci. 2016, 2, 506−516
511
proposed that this protein is a nuclear protein because it has
been identiﬁed in the nuclear fraction of the cell lysate and
possessed a predicted nuclear localization signal.41,42 However,
immunoﬂuorescence images of FKBP25 in our experiment
using HeLa cells and other reported immunoﬂuorescence
images of FKBP25 in other cell lines (e.g., U2OS, A431,
U251MG) originating from diﬀerent tissue samples support
that FKBP25 is a cytoplasmic protein that is not localized in the
Figure 5. Crystal structure of FKBP25−FRB−rapamycin ternary complex. (A) Ribbon diagram shows the overall structure of the FKBP25 (blue)−
FRB (pink)−rapamycin (yellow) ternary complex. The crystal structure of FKBP25−FRB−rapamycin was determined by molecular replacement
using the FKBP12−FRB−rapamycin structure as a search model and reﬁned with native data to 1.67-Å resolution. Rapamycin is shown as a stick
model with oxygen and nitrogen atoms colored in red and blue, respectively. (B) Structural alignment among FKBP25−FRB−rapamycin (blue),
FKBP12−FRB−rapamycin (red), FKBP51−FRB−rapamycin (green), and FKBP52−FRB−rapamycin (light blue) reveals that the overall structure
of FKBP25 highly resembles other FKBP−FRB−rapamycin ternary complex structures. The molecular structure of rapamycin in FKBP12−FRB−
rapamycin, FKBP51−FRB−rapamycin, and FKBP52−FRB−rapamycin is omitted in the ﬁgure for clarity. (C) Ribbon diagram shows the
dimerization mediated by rapamycin (yellow) between FKBP25 (blue) and FRB (pink). Oxygen and nitrogen atoms are red- and blue-colored,
respectively. The yellow dotted lines indicate intermolecular hydrogen bonds. (D) The picture shows C2085 covalently modiﬁed with an arsenic
atom from cacodylic acid (see text for details). (E) Protein surface presentation shows hole formation in FRB by FKBP25−rapamycin complexation.
C2085 is colored pink. Dimethyl arsenic group is colored blue. M2047 and M2089 are colored orange. Y2088 is colored magenta and D205 of
FKBP25 is colored green.
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nucleus.43 Thus, the physiological role of FKBP25 should be
reconsidered as a rapamycin-induced FRB interactor in the
context of the cytoplasm. Because FKBP25 has not been
previously discussed as a rapamycin-dependent interactor for
FRB in the cytoplasm, we performed further experiments to
identify the crystal structure of the ternary molecular complex
of FKBP25−rapamycin−FRB to reveal its physiological role in
mTOR signaling.
Structural Basis for FKBP25 Binding to FRB Depend-
ent on Rapamycin. To further investigate the binding of
FKBP25 to FRB, we determined the crystal structure of the
FKBP25−FRB complex in the presence of rapamycin at a 1.67
Å resolution (Figure 5A). The overall structure of FKBP25−
FRB−rapamycin highly resembles the FKBP12−FRB−rapamy-
cin, FKBP51−FRB−rapamycin, and FKBP52−FRB−rapamycin
structures with root-mean-square deviations (RMSDs) of 1.0 Å,
1.2 Å, and 0.9 Å, respectively (Figure 5B).44,45 The crystal
structures demonstrate that FKBP25 directly interacts with
FRB in a rapamycin-dependent manner, such that the
rapamycin is located in the center, capped by FRB and
FKBP25 at each end. Because the binding conformation of the
FKBP25−rapamycin−FRB complex is very similar to the
FKBP12−rapamycin−FRB complex, we speculate that the
physiological role of FKBP25 should be related to inhibit
mTOR activity in the presence of rapamycin. Our hypothesis
can be supported by previously reported in vitro experiment
results which showed that FKBP25 inhibits mTOR activity with
rapamycin (IC50 = 2.61 nM).
45
The direct interactions observed in the FRB−FKBPs
(FKBP12/FKBP51/FKBP52) complex, mediated by the 40s
and 80s loops of FKBPs, as well as the rapamycin-dependent
interactions are highly conserved in the FRB−FKBP25 complex
(Figure 5A,C). However, unexpectedly the 80s loop of FKBP25
was found to be closer to the α4 helix of FRB compared to
other FKBPs when analyzed with structural alignment. For such
proximal contact, novel interactions mediated by the D205
residue of FKBP25 are newly established. The D205 residue is
absolutely conserved among FKBP25 orthologs in metazoan
but is absent in other FKBP proteins, including FKBP12,
FKBP51, and FKBP52 (Figure S2). In particular, the main
chain of D205 from FKBP25 makes hydrogen bonds with the
main chain of G2092 and the side chain of Y2088 from FRB
through the buried water molecules. In addition, the side chain
of D205 in FKBP25 makes hydrogen bonds with the side chain
of Y2038 from FRB (Figure 5C). Interestingly, in order to
make novel contacts, the axes of the α3 and α4 helices of FRB
were pulled out around 10 deg toward the 80s loop of FKBP25
compared to the helices in other FKBPs−FRB complexes
(Figure 5B).
Surprisingly, the conformational changes of these helices in
FRB generate a hole where C2085 of FRB is located at the
bottom, and this residue was modiﬁed by dimethyl arsenic
group (Figure 5D). Characterization of the arsenic atom in the
protein complex was performed by anomalous scattering
scanning and X-ray absortption spectroscopy (Figure S3).
The dimethylarsenic group is known to be produced from the
reaction between cacodylic acid and dithiothreitol in the
crystallization buﬀer.46 It was previously reported that dimethyl
arsenic modiﬁcation occurred with a reactive cysteine residue in
the enzyme active site.47 Furthermore, we found that this hole
is a methionine-rich space given the presence of M2089 and
M2047. Thioethers of these methionine residues may introduce
transition metal ions from the surface to the bottom of the
hole.48 Because this metalloid coordination at C2085 of FRB
was not observed in ternary complex structures of other FKBPs,
we postulate that FKBP25 should play a unique physiological
role related to metallomics in the mTOR signaling pathway.
To investigate the physiological roles of the predicted metal
binding site of FRB in the complex with FKBP25, we
performed site-directed mutagenesis (e.g., C2085A and
M2047L) of the amino acid residues in the predicted metal
binding sites of FRB. We measured the circular dichroism
(CD) spectrum of puriﬁed C2085AFRB, M2047LFRB, and wild type
FRB with FKBP25 depending on the metal treatment. As
shown in Figure S6A, wavelength scanning of the complexes
revealed that no secondary structures changed when the metal
bound to the complex. We also measured the melting
temperatures (Tm values) of the complexes in thermal
denaturation experiments for checking structural stability of
each complex. As shown in Figure S6B, the melting
temperature of the FRB−rapamycin−FKBP25 ternary complex
(Tm = 71.06 °C) was increased by approximately 5 and 17 °C
compared to that of FRB (Tm = 65.76 °C) and FKBP25 (Tm =
54.43 °C) alone, respectively, suggesting that FKBP25 binding
to FRB signiﬁcantly increases the protein stability of the ternary
complex (Figure S6B).
Tm values of the FKBP25−rapamycin−wild type FRB
complex was slightly increased from 71.06 to 71.55 °C upon
addition of the arsenic atom (Figure S6B). We also found that
Tm value of
C2085AFRB−rapamycin−FKBP25 was increased
from 70.68 to 71.03 °C upon addition of the arsenic atom,
while M2047LFRB−rapamycin−FKBP25 complex showed a
decreased Tm value from 69.09 to 68.59 °C upon addition of
the arsenic atom (Figure S6C,D). This result suggests that
metal binding of the M2047 residue of FRB may contribute to
the stability of the FRB−rapamycin−mFKBP25 ternary
complex (Figure S6E).
The importance of metal coordination of FRB is further
supported by the sequence conservation of M2047, which was
predicted to be a key residue involved in metal coordination in
FRB based on the crystal structure (Figure 5E). Surprisingly,
M2047 is absolutely conserved among 10 other species, from
metazoan to yeast (Figure S6F).49 We also found M2047LFRB
and its ternary complex with rapamycin and FRB showed lower
Tm values than those of wild type FRB and its ternary complex,
which indicates this site mutation signiﬁcantly aﬀected the
stability, although the secondary structure was unaﬀected by the
mutation (Figure S6A,D,E). Collectively, these results suggest
that the metal coordination with the M2047 residue play an
important role to increase stability of the ternary complex of
FRB−rapamycin−FKBP25. Further analysis is required to
address the physiological functions of metal coordination to
the mTOR complex in living cells.
■ DISCUSSION
In total, 18 diﬀerent FKBP proteins are known to be expressed
in various human tissues, and all of these proteins contain the
PPIase domain.18 However, not all of these proteins show
strong binding aﬃnity toward rapamycin.50 Among these
proteins, FKBP25 and FKBP12 are known to be the best
rapamycin binders (Ki of FKBP25 = 0.9 nM, Ki of FKBP12 =
0.26 nM).51 Mar̈z et al.44 reported that hFKBP12 and
hFKBP25 showed similar half-maximal eﬀective concentration
(EC50) values of rapamycin for ternary complex formation (3.8
nM for FKBP12, 4.3 nM for FKBP25), whereas other cytosolic
FKBPs showed low aﬃnity (e.g., 25 nM for FKBP51 and 25.5
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nM for FKBP52). We consider that the lower ternary protein
complex binding aﬃnity of FKBP51 and FKBP52 can explain
why these proteins were not labeled by FRB−pBirA, because
stronger competitor proteins (e.g., FKBP12 or FKBP25) were
present in the cytoplasm.
Although FKBP12 was not identiﬁed in our data set, our
results do not exclude the possibility that FKBP12 is a main
interaction partner of FRB−pBirA in the presence of
rapamycin, because FKBP12 is a short protein that lacks a
ﬂexible loop with an accessible lysine residue, which are also
properties of FKBP25 (Figure 4A). This could be considered as
a false-negative result of pBirA labeling, which requires an
accessible lysine residue of proximal proteins. However, our
data suggest that FKBP25 is likely to be one of the main
interactors of FRB in the presence of rapamycin because
FKBP25 has a strong possibility to be proximally biotinylated
by FRB−pBirA even if FKBP12 is present as a strong
competitor in the cytoplasm.
For comparison with other proximity labeling methods, we
used FRB-conjugated engineered ascorbate peroxidase4−6
(FRB−APEX2) and determined whether FKBP25 was labeled
in the presence of rapamycin. As shown in Figure S4 we found
that FKBP25 was not biotinylated by FRB−APEX2. Because
there are no or fewer accessible exposed tyrosine residues at the
ﬂexible loop of FKBP25, we postulated that proximity labeling
by biotin-phenoxyl radical coupling should hardly occur.4−6 In
contrast, there were several solvent-exposed lysine residues
(K80, K86, and K89) at the loop, which would be favorable for
proximity labeling by pBirA.
From a bioinformatics analysis of FKBP25, we determined
that more than 10% of cancers originating from the pancreas,
lung, and upper aerodigestive tract had signiﬁcantly higher
expression of FKBP25 (see Supporting Information). Thus, this
high expression of FKBP25 in cancer tissues could make them a
candidate for rapamycin or rapamycin analogue treatments for
achieving eﬃcient inhibition of mTOR activity, which is deeply
related to tumorigenesis.15
■ CONCLUSION
We identiﬁed that FKBP25 is a strong interactor of mTOR
protein in the presence of rapamycin in live cells through a new
workﬂow designed to analyze labeled peptides from proximity
labeling. We also successfully obtained the X-ray crystal
structure of the ternary molecular complex of FKBP25−
rapamycin−FRB. In this crystal structure, we could observe that
metalloid modiﬁcation on C2085 of FRB at the bottom of the
hole which was induced by rapamycin−FKBP25. Our result
implies that FKBP25 might play a unique role related to
metallomics in the mTOR pathway.
■ EXPERIMENTAL SECTION
Proximity Labeling by FRB−pBirA. For the proximity
labeling experiment in living cells, we prepared a pBirA fusion
construct of the FRB domain at the C-terminus (FRB−pBirA)
in a mammalian expression vector (pCDNA5) and evaluated
the expression pattern and biotinylation activity of FRB−pBirA-
transfected cells by immunoﬂuorescence imaging experiments
(Figure 1B). For this Western blotting experiment, FRB−pBirA
was transiently expressed in HEK293T cells and incubated with
50 μM biotin for 16 h at 37 °C. For the rapamycin-treated
sample (FRB-R), the cells were treated with 100 nM of
rapamycin for 16 h along with biotin, whereas in the no
rapamycin-treated sample (FRB-NoR), the cells were only
treated with biotin at this step. After biotin labeling, the cells
were sacriﬁced and the biotinylated proteins were analyzed by
streptavidin-horseradish peroxidase (SA-HRP) Western blot-
ting (Figure 1C,D). The detailed experimental procedures
experiments are described in Supporting Information.
Mass Spectrometry Identiﬁcation of Biotin-Labeled
Sites by pBirA. The biotinylated peptides were eluted with a
95% formamide solution, which is acceptable for mass
spectrometer injection. In the tandem mass spectrometry
analysis of the SA-eluted peptides, a total of 4144 peptides
containing a biotin-modiﬁed lysine (lysine+226 Da) residue
were ﬁltered from the total of four biological replicates of
pBirA-labeled samples (FRB-R-Rep1, FRB-R-Rep2, FRB-NoR-
Rep1, FRB-NoR-Rep2) since they showed the lowest 1.0% false
discovery rate (FDR). We ﬁltered these peptides with more
than or equal to 2 exclusive spectral counts per labeled lysine
site to obtain labeled peptidome information with higher
conﬁdence.
Circular Dichroism Analysis. Structural change and
stability in the FRB, FKBP25, and FRB−rapamycin−FKBP25
ternary complex (15 μM) were monitored by a circular
dichroism (CD) spectrometer (Jasco J-815) at various
wavelengths (190−260 nm). Conformational changes for
each protein were also monitored at various temperatures by
scanning with a CD spectrometer. The temperature was raised
from 30 to 95 °C over a 13 min period with detection on 222
nm wavelength. All the samples used here were prepared in
buﬀer A (25 mM sodium phosphate, 150 mM NaCl, pH 7.5).
For incorporation of the arsenic atom to the FRB protein, we
incubated puriﬁed proteins with 100 mM cacodylate pH 6.5
and 5 mM DTT for 2 h at 4 °C, and proteins were applied onto
a HiTrap desalting column (GE Healthcare) equilibrated with
buﬀer A. All mutants were generated by a PCR based site-
directed mutagenesis method, and mutation in the FRB
sequence was conﬁrmed by DNA sequencing.
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